Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

17.05.2019 | short review | Ausgabe 2/2019 Open Access

memo - Magazine of European Medical Oncology 2/2019

Lung cancer screening from the oncologist’s perspective

How does lung cancer treatment benefit from the NELSON trial

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 2/2019
Autoren:
MD. PhD. Florian Kocher, MD Georg Pall
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

With the release of the survival results from the NELSON lung cancer screening trial there is now additional evidence that low-dose computed tomography (LDCT) screening leads to a reduction of lung cancer mortality in high-risk individuals. These results clearly show that LDCT screening has to be implemented in daily routine. However some questions like the most efficient screening intervals, duration of screening or the most appropriate participant selection are still not finally answered. This article provides a view on lung cancer screening from an oncologist’s perspective.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2019

memo - Magazine of European Medical Oncology 2/2019 Zur Ausgabe